Osaghae Ikponmwosa, Chido-Amajuoyi Onyema Greg, Khalifa Banda A A, Talluri Rajesh, Shete Sanjay
Department of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, USA.
Cancers (Basel). 2023 Dec 13;15(24):5822. doi: 10.3390/cancers15245822.
Despite growing interest in the use of cannabis for the treatment of cancer-related symptoms, there are limited studies that have assessed the use pattern, type, and mode of delivery of cannabis products used by cancer survivors. This study describes the current state of the use pattern, product type, and mode of delivery of cannabis used by cancer survivors. This was a cross-sectional study of cancer survivors from 41 U.S. states who received treatment at the largest NCI-designated comprehensive cancer center. The weighted prevalence of the use patterns, product types, and modes of delivery of cannabis used by cancer survivors was estimated. A total of 1886 cancer survivors were included in the study, with 915 (48% [95% CI: 45-51]) reporting ever using cannabis. Of survivors who had ever used cannabis, 36% (95% CI: 33-40) were current users. Among survivors who reported cannabis use after diagnosis, 40% used cannabis during and after cancer treatment, 35% used cannabis during treatment, and 25% used cannabis after completing their cancer treatment. Additionally, 48% of survivors reported an increase in cannabis use since cancer diagnosis. The commonest types of cannabis products used by cancer survivors were dry leaf cannabis (71%), cannabidiol (CBD) oil (46%), and cannabis candy (40%). Moreover, cancer survivors frequently used baked goods (32%), creams and gels (21%), and tinctures (18%). Furthermore, among ever users, the predominant mode of use was cannabis inhalation/smoking (69%) compared to eating/drinking (59%). More so, the common mode of inhalation/smoking of cannabis products were rolled cannabis cigarettes (79%), pipes (36%), water pipes (34%), vaporizers or vapes (14%), and e-cigarette devices (14%). A substantial number of cancer survivors use cannabis during cancer treatment, with increased use following cancer diagnosis. The forms and modes of delivery of cannabis varied among survivors, with most survivors inhaling or smoking cannabis. There is a need to educate healthcare providers (HCPs) and survivors on current evidence of cannabis use and strengthen cannabis regulatory frameworks to optimize benefits and minimize adverse events from cannabis use during cancer treatment.
尽管人们对使用大麻治疗癌症相关症状的兴趣日益浓厚，但评估癌症幸存者使用大麻产品的使用模式、类型和给药方式的研究却很有限。本研究描述了癌症幸存者使用大麻的使用模式、产品类型和给药方式的现状。这是一项对来自美国41个州、在最大的美国国立癌症研究所指定的综合癌症中心接受治疗的癌症幸存者进行的横断面研究。估计了癌症幸存者使用大麻的使用模式、产品类型和给药方式的加权患病率。共有1886名癌症幸存者纳入研究，其中915名（48%[95%CI：45 - 51]）报告曾使用过大麻。在曾使用过大麻的幸存者中，36%（95%CI：33 - 40）为当前使用者。在诊断后报告使用大麻的幸存者中，40%在癌症治疗期间及之后使用大麻，35%在治疗期间使用大麻，25%在完成癌症治疗后使用大麻。此外，48%的幸存者报告自癌症诊断以来大麻使用量增加。癌症幸存者使用的最常见大麻产品类型是干叶大麻（71%）、大麻二酚（CBD）油（46%）和大麻糖（40%）。此外，癌症幸存者经常使用烘焙食品（32%）、乳膏和凝胶（21%）以及酊剂（18%）。此外，在曾使用者中，主要的使用方式是吸入/吸食大麻（69%），而食用/饮用大麻的比例为59%。更有甚者，大麻产品常见的吸入/吸食方式是卷制大麻卷烟（79%）、烟斗（36%）、水烟管（34%）、蒸发器或电子烟（14%）以及电子烟设备（14%）。相当数量的癌症幸存者在癌症治疗期间使用大麻，且癌症诊断后使用量增加。大麻的形式和给药方式在幸存者中各不相同，大多数幸存者吸入或吸食大麻。有必要就大麻使用的当前证据对医疗保健提供者（HCPs）和幸存者进行教育，并加强大麻监管框架，以优化益处并尽量减少癌症治疗期间使用大麻的不良事件。
